Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Jazz Pharmaceuticals JAZZ has reached a milestone that most conventional cannabis players are yet to achieve — generating sustained, billion-dollar revenues from a cannabis product. In its recent earnings announcement, Jazz reported that its cannabidiol (CBD) therapy Epidiolex surpassed $1 billion in annual product sales, officially entering blockbuster territory. The achievement marks a turning point for the company's cannabis exposure, transforming Epidiolex from a niche orphan-drug asset into a durable growth engine. With the achievement of this milestone, it is worth assessing Jazz's strengths and weaknesses to determine whether the stock deserves a place in investors' portfolios. Epidiolex — Powering JAZZ's Cannabis Story Jazz's involvement in the cannabis sector centers on Epidiolex, which is approved for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. The drug was originally developed by GW Pharmaceuticals, a p
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (JAZZ) is now covered by Barclays PLC. They set an "overweight" rating and a $224.00 price target on the stock.MarketBeat
- A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Quarter And 2026 Guidance [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 2/27/26 - Form 144
- 2/27/26 - Form 144
- 2/26/26 - Form 144
- JAZZ's page on the SEC website